Background Colchicine prophylaxis is the single most important factor in ameliorating FMF for the prevention of both attacks and secondary amyloidosis. It is known that some cases donot respond to colchicine prophylaxis.
Objectives The aim of the present study was to evaluate the exact proportion of those patients who do not respond to the colchicine and to characterize their demographic, sociodemographic and clinical aspects.
Methods 108 patients with FMF were included in our study. The demographic (age, gender), socioeconomic (education level, employment stataus, economic income level) and clinical features (age at onset of FMF, age at FMF diagnosis, family history of FMF, mean duration of colchicine use and mean daily colchicine dose) of the patients were evaluated. The patients unresponsive to colchicine therapy according to their statement were recorded. Also with another question, patient's routine colchicines-consuming habits were asked in a self-answering format. Data were analysed with the chi-square test and Fisher's exact test.
Results There were 50 female and 58 male patients with a mean age of 42.4±11.3 years. The mean age at FMF onset and at FMF diagnosis were found as 14.3±10.5 and 19.1±12.9 years respectively. % 16 of the patients defined themselves as “suffering from attacks inspite of regular colchicine”. Irregular colchicine usage was determined in % 11 of the patients who were considered as “unresponsive to colchicine therapy” according to their statements. In spite of regular colchicine regimen, attacks were present in 5% of the patients in our study. Although there was no difference in demographic and clinical aspects, patients with irregular colchicine usage were found to be from lower socioeconomic backgrounds, had less education and more unemployment (p<0.001).
Conclusions In conclusion, regular colchicine usage anemnesis may be misleading in the first evaluation and this risk seems to be higher in patients with lower socioeconomic backgounds. Routine colchicine consuming habits should be detailed in patients with FMF before claiming its failure.
Disclosure of Interest None declared